Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Penny Asbell, MD, FACS, MBA

Advertisement

Articles by Penny Asbell, MD, FACS, MBA

Omega 3s

From DREAM to reality

ByPenny Asbell, MD, FACS, MBA,Cheryl Guttman Krader, BS, Pharm
July 25th 2018
Advertisement

Latest Updated Articles

  • Omega 3s
    From DREAM to reality

    Published: July 25th 2018 | Updated:



Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases

2

What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient

3

Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5

4

AAO 2025: A study of retinal vasculitis events with intravitreal agents

5

Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us